We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Practical advice for clinicians caring for immunocompromised persons who wish to travel or who have travelled to Zika-affected countries or areas.
May cause skin irritation, particularly in children with eczema, possibly due to sodium lauryl sulfate content.
Guidance for public health professionals to manage scabies cases and outbreaks, including recommendations for diagnosis, treatment and wider control measures.
If you suspect exfoliative dermatitis caused by an adverse drug reaction to ustekinumab, stop treatment.
Some batches of gentamicin sulphate active pharmaceutical ingredient (API) used to manufacture gentamicin may contain higher than expected levels of histamine, which is a residual from the manufacturing process. Monitor pati…
Information on acrylonitrile (2-propenenitrile; cyanoethylene; vinyl cyanide) for use in responding to chemical incidents.
Public Assessment Report (PAR) reviewing available safety data for topical steroid withdrawal reactions, which have been associated with topical corticosteroids.
Caution in Use: Distribute to Hospital Pharmacy, Ward and Operating Theatre Level
Accord Healthcare have informed us of an error with the patient information leaflets (PILs) that have been packaged in some Rosuvastatin products.
Information for healthcare professionals on diphtheria anti-toxin (DAT).
A recent Europe-wide review of the safety information for alli has led to a number of updates, which bring the product information in line with that for Xenical.
…Advise patients to be vigilant for the signs of severe skin reactions and to seek urgent medical advice if they occur.
Information on naphthalene (also called naphthene or naphthalin), for responding to chemical incidents.
Public consultation on a set of proposals to make Gina 10 microgram vaginal tablets (Estradiol) available from pharmacies.
Healthcare professionals prescribing nitrofurantoin should be alert to the risks of pulmonary and hepatic adverse drug reactions and advise patients to be vigilant for the signs and symptoms in need of further investigation.
Rarely, severe adverse effects can occur on stopping treatment with topical corticosteroids, often after long-term continuous or inappropriate use of moderate to high potency products.…
Information on the smallpox vaccination used to protect you against the monkeypox virus (MPXV).
Manufactured by Abbott – some users who are experiencing an immune response to the adhesive are applying creams, patches or sprays under their sensor to reduce skin reactions, which may affect device performance.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).